Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25
NUTRITION; GYN
Formative Assessment of the Effect of 'Cramp Bites' Intake on Primary Dysmenorrhea in Women Aged 18-25: A Placebo-Controlled Trial
1 other identifier
interventional
12
1 country
1
Brief Summary
85 percent of women of reproductive age experience consistent period cramps/menstrual pain, and 60% indicate that they do not use painkillers to relieve menstrual symptoms; there is a need for natural and non-medicative supplements to dysmenorrhea. The purpose of this clinical trial is to examine the effect of 'Cramp Bites'--classified by a mixture of natural ingredients researched to help with period pain--on women suffering from primary dysmenorrhea: this will be done through providing participants with the snack and surveying them on how it changes their period symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Jul 2022
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2022
CompletedFirst Submitted
Initial submission to the registry
January 17, 2024
CompletedFirst Posted
Study publicly available on registry
January 29, 2024
CompletedApril 12, 2024
April 1, 2024
2 months
January 17, 2024
April 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Visual Analogue Scale for Spasmodic Cramps
Participants rate their spasmodic cramp severity before and after eating either Cramp Bites or the Placebo Snack using the Visual Analogue Scale. This is on a scale from 0 to 10, where 0 represents no cramps and 10 indicates extreme abdominal cramping.
Participants complete this survey when they experience cramps: once before they consume their snack, and once after. Completion time for each survey is 7 minutes.
Visual Analogue Scale for Congestive Cramps
Participants rate their congestive cramp severity before and after eating either Cramp Bites or the Placebo Snack using the Visual Analogue Scale. This is on a scale from 0 to 10, where 0 represents no cramps and 10 indicates extreme abdominal cramping.
Participants complete this survey when they experience cramps: once before they consume their snack, and once after. Completion time for each survey is 7 minutes.
Secondary Outcomes (1)
Menstrual Symptom Questionnaire (MSQ)
Participants complete this questionnaire with a researcher before the study. Time to complete this questionnaire is 15 minutes.
Other Outcomes (1)
Product Feedback Form
Participants were asked to fill out this survey at the end of the study. Completion time was 5 minutes.
Study Arms (2)
Granola Bites
PLACEBO COMPARATORThis snack contains no known spices or nutrients that have been shown to help with spasmodic or congestive dysmenorrhea. It is the same shape and size as the active comparator.
Cramp Bites
ACTIVE COMPARATORThis snack contains spices and ingredients that have been shown to help with both spasmodic and congestive dysmenorrhea. It is the same shape and size as the placebo comparator.
Interventions
Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
Eligibility Criteria
You may qualify if:
- Women between the ages of 18 and 25 who experience primary dysmenorrhea and have no pathological disorders.
You may not qualify if:
- Pregnancy or breast feeding within 6 months
- Primary or secondary amenorrhea
- Body mass index less than the 1st percentile or body weight above 300 lbs
- Undergoing menstrual suppression by medicative means
- Unwilling to avoid painkillers (ibuprofen or naproxen) for the duration of the study unless absolutely necessary
- Has allergies or aversions to ingredients used in either Cramp Bites or the Placebo Snack
- Not fluent in English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cornell Universitylead
- Laidlaw Foundationcollaborator
- Epperson Fundcollaborator
- Beck Fellowshipcollaborator
- Dan Cane Fundcollaborator
Study Sites (1)
Cornell University
Ithaca, New York, 14853, United States
Related Publications (10)
Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015 Nov-Dec;21(6):762-78. doi: 10.1093/humupd/dmv039. Epub 2015 Sep 7.
PMID: 26346058BACKGROUNDFerries-Rowe E, Corey E, Archer JS. Primary Dysmenorrhea: Diagnosis and Therapy. Obstet Gynecol. 2020 Nov;136(5):1047-1058. doi: 10.1097/AOG.0000000000004096.
PMID: 33030880BACKGROUNDItani R, Soubra L, Karout S, Rahme D, Karout L, Khojah HMJ. Primary Dysmenorrhea: Pathophysiology, Diagnosis, and Treatment Updates. Korean J Fam Med. 2022 Mar;43(2):101-108. doi: 10.4082/kjfm.21.0103. Epub 2022 Mar 17.
PMID: 35320895BACKGROUNDChen CX, Kwekkeboom KL, Ward SE. Self-report pain and symptom measures for primary dysmenorrhoea: a critical review. Eur J Pain. 2015 Mar;19(3):377-91. doi: 10.1002/ejp.556.
PMID: 25059384BACKGROUNDChesney MA, Tasto DL. The development of the menstrual symptom questionnaire. Behav Res Ther. 1975 Oct;13(4):237-44. doi: 10.1016/0005-7967(75)90028-5. No abstract available.
PMID: 1238078BACKGROUNDGuimaraes I, Povoa AM. Primary Dysmenorrhea: Assessment and Treatment. Rev Bras Ginecol Obstet. 2020 Aug;42(8):501-507. doi: 10.1055/s-0040-1712131. Epub 2020 Jun 19.
PMID: 32559803BACKGROUNDDirekvand-Moghadam A, Khosravi A. The impact of a novel herbal Shirazi Thymus Vulgaris on primary dysmenorrhea in comparison to the classical chemical Ibuprofen. J Res Med Sci. 2012 Jul;17(7):668-70.
PMID: 23798928BACKGROUNDMates L, Popa DS, Rusu ME, Fizesan I, Leucuta D. Walnut Intake Interventions Targeting Biomarkers of Metabolic Syndrome and Inflammation in Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Antioxidants (Basel). 2022 Jul 21;11(7):1412. doi: 10.3390/antiox11071412.
PMID: 35883903BACKGROUNDGutman G, Nunez AT, Fisher M. Dysmenorrhea in adolescents. Curr Probl Pediatr Adolesc Health Care. 2022 May;52(5):101186. doi: 10.1016/j.cppeds.2022.101186. Epub 2022 May 4.
PMID: 35523674BACKGROUNDNegriff S, Dorn LD, Hillman JB, Huang B. The measurement of menstrual symptoms: factor structure of the menstrual symptom questionnaire in adolescent girls. J Health Psychol. 2009 Oct;14(7):899-908. doi: 10.1177/1359105309340995.
PMID: 19786516BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Women's Health Student
Study Record Dates
First Submitted
January 17, 2024
First Posted
January 29, 2024
Study Start
July 21, 2022
Primary Completion
September 15, 2022
Study Completion
October 31, 2022
Last Updated
April 12, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share
Due to the privacy protection of participants, individual participant data will not be disclosed.